Zimmer Biomet Holdings, Inc. (ZBH): Price and Financial Metrics


Zimmer Biomet Holdings, Inc. (ZBH)

Today's Latest Price: $111.28 USD

9.37 (9.19%)

Updated Apr 8 8:04pm

Add ZBH to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 132 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

ZBH Stock Summary

  • ZBH has a higher market value than 92.92% of US stocks; more precisely, its current market capitalization is $19,278,100,536.
  • With a one year PEG ratio of 0.28, Zimmer Biomet Holdings Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 5.14% of US stocks.
  • Over the past twelve months, ZBH has reported earnings growth of 6,090.16%, putting it ahead of 99.82% of US stocks in our set.
  • Stocks that are quantitatively similar to ZBH, based on their financial statements, market capitalization, and price volatility, are DRAD, SD, CREG, CCCL, and BVN.
  • ZBH's SEC filings can be seen here. And to visit Zimmer Biomet Holdings Inc's official web site, go to www.zimmerbiomet.com.
ZBH Daily Price Range
ZBH 52-Week Price Range

ZBH Stock Price Chart More Charts


ZBH Price/Volume Stats

Current price $111.28 52-week high $161.11
Prev. close $101.91 52-week low $74.37
Day low $102.68 Volume 2,937,200
Day high $112.00 Avg. volume 1,751,538
50-day MA $125.52 Dividend yield 0.94%
200-day MA $135.18 Market Cap 22.97B

Zimmer Biomet Holdings, Inc. (ZBH) Company Bio


Zimmer Biomet Holdings designs, develops, manufactures, and markets orthopaedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. The company was founded in 1927 and is based in Warsaw, Indiana.

ZBH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$111.28$51.94-49%

Below please find a table outlining a discounted cash flow forecast for ZBH, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Zimmer Biomet Holdings Inc ranked in the 25th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 49%. In terms of the factors that were most noteworthy in this DCF analysis for ZBH, they are:

  • As a business, ZBH is generating more cash flow than 79.44% of positive cash flow stocks in the Healthcare.
  • Zimmer Biomet Holdings Inc's weighted average cost of capital (WACC) is 7%; for context, that number is higher than just 22.92% of tickers in our DCF set.
  • Zimmer Biomet Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-50%
1%-50%
2%-49%
3%-49%
4%-48%
5%-48%

Want more companies with a valuation profile/forecast similar to that of Zimmer Biomet Holdings Inc? See VREX, ABT, ENZ, WST, and BIO.


ZBH Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ZBH Latest Social Stream


Loading social stream, please wait...

View Full ZBH Social Stream

ZBH Price Returns

1-mo -5.71%
3-mo -25.62%
6-mo -18.11%
1-year -12.94%
3-year -5.00%
5-year -1.25%
YTD -25.47%
2019 45.37%
2018 -13.30%
2017 17.86%
2016 1.46%
2015 -8.80%

ZBH Dividends

Ex-Dividend DateTypePayout AmountChange
Loading, please wait...
View Full ZBH Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8055 seconds.